Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


Molecular Profile CD274 positive
Therapy Camrelizumab + Rivoceranib
Indication/Tumor Type lung non-squamous non-small cell carcinoma
Response Type not predictive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive lung non-squamous non-small cell carcinoma not predictive Camrelizumab + Rivoceranib Phase Ib/II Actionable In a Phase Ib/II trial, combined Camrelizumab (SHR-1210) and Rivoceranib (apatinib) treatment in patients with CD274 (PD-L1)-positive (TPS>=1%; n=25) non-squamous non-small cell lung cancer resulted in a similar objective response rate (36.0%, 9/25 vs 22.7%, 15/66; p=0.20), disease control rate (72.0%,18/25 vs 71.2%, 47/66; p=0.94), and median progression-free survival (6.8 vs 5.1 months; p=0.29) to patients with CD274 (PD-L1)-negative (TPS<1%; n=66) tumors (PMID: 33323401; NCT03083041). 33323401
PubMed Id Reference Title Details
(33323401) Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced non-squamous NSCLC previously treated with chemotherapy. Full reference...